Sanjeev
Nanda, a British-Indian business tycoon is all set forth to move into the
pharmaceutical business with ISHVAN Pharmaceuticals Limited. The company has
hopes of becoming a fully integrated pharmaceutical company with its focus on production
and supply of a variety of innovative and affordable medicinal drugs, medical
devices and diagnostics to different pharmaceutical markets all over the world.
The Managing
Director of ISHVAN Pharmaceuticals Limited, Sanjeev Nanda happens to be
prominent entrepreneur with ample experience in different sectors like hotels
& hospitality, food & beverages, heavy engineering, IT and others. The
entrepreneur is also the co-owner of “The Claridges” in New Delhi and recently on
Dec’ 2016, he sold the iconic “Dhaba” of Claridges to Goldman Sachs and Max
Ventures & Industries Limited investment, Azure Hospitality. This fueled a
lot of speculations about the future plans of Mr. Sanjeev Nanda. Also, he was
the one who setup the Taj Hotel in Dubai and was instrumental behind the
establishment of “Billionaire Mansion” at the Taj, Dubai. Being a versatile
leader, it is expected that he will adopt the best strategies and skills to
take ISHVAN towards the right path of progress.
The primary
focus of the pharmaceutical company will be to offer turn-key solutions and
expertise as well as bring in assistance towards improving the local Russian
pharmaceutical infrastructure. Also, ISHVAN pharmaceuticals under the
leadership of Sanjeev Nanda will put in every effort to offer patients with
access to latest generation of medical drugs for treatment of diseases like TB,
HIV and Hepatitis. In order to fulfill its objective, ISHVAN will target
different markets in phases where first, it will focus on Russian and Eurasian
markets then shift its focus towards Asian and African markets. A way forward
strategy has already been identified by ISHVAN pharmaceuticals and associations
are being made with different foreign and Indian companies to evolve the
business. After a lot of scrutiny, advanced negotiations are being made with
reputed pharmaceutical companies like Laurus, Mylan, Cipla, etc. to acquire
technology required for development and production of finished drugs (FDF) and
drug substances (API). The company has also obtained MA’s (market
authorization) from Cannon and Rowtec which is essential for the introduction
of generic equivalent of a said product after expiry of the patent.
The vast
number of available opportunities in the Russian market will be the fundamental
driving force of ISHVAN pharmaceuticals. By bringing in the newer generation
products from different partners, ISHVAN will present the Russian market with
safer and effective medication as well as better treatment goals. Also the
products are expected to take up a majority share in the market as there is no
foreseeable or present competition. The operations of ISHVAN will start with a
total investment of US $60 million in Russia by focusing on niche segments like
HIV/AIDS, Hepatitis and TB. The HIV/AIDS population in Russia is the fastest
growing in the world and Russia also happens to be the 8th most
populated country in the world terms of HIV patients. Reports state that 70% of
new incidences of HIV/AIDS affect the working population within the age bracket
of 29-30 years. Thus, the arrival of ISHVAN with its advanced solutions and new
generation products is expected to help Russia put a stop to this growing
concern. After establishing its operation in Russia, Sanjeev Nanda’s
pharmaceutical firm will begin its next phase of operation by bringing in IP
backed novel drugs, newer treatment options and better platforms for therapy
areas related to vaccines, oncology, blood products and biological drugs along
with innovative options in devices and diagnostics. If all goes well, ISHVAN
with its focus on driving innovation and technology in the field of pharmacy
will certainly bring in huge improvements in global health issues throughout
different geographies.
No comments:
Post a Comment